Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SML3229

Sigma-Aldrich

LY3000328

≥95% (HPLC)

Synonyme(s) :

(3R,4S)-4-(4-Fluorobenzamido)-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-3-yl methylcarbamate, LY 3000328, LY-3000328, N-[(3R,4S)-3,4-Dihydro-3-[[(methylamino)carbonyl]oxy]-6-[4-(3-oxetanyl)-1-piperazinyl]-2H-1-benzopyran-4-yl]-4-fluorobenzamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C25H29FN4O5
Numéro CAS:
Poids moléculaire :
484.52
Numéro MDL:
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

Pureté

≥95% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

−20°C

Chaîne SMILES 

O=C(C(C=C1)=CC=C1F)N[C@H]2C3=CC(N4CCN(C5COC5)CC4)=CC=C3OC[C@@H]2OC(NC)=O

InChI

1S/C25H29FN4O5/c1-27-25(32)35-22-15-34-21-7-6-18(29-8-10-30(11-9-29)19-13-33-14-19)12-20(21)23(22)28-24(31)16-2-4-17(26)5-3-16/h2-7,12,19,22-23H,8-11,13-15H2,1H3,(H,27,32)(H,28,31)/t22-,23-/m0/s1

Clé InChI

NDEBZCZEAVMSQF-GOTSBHOMSA-N

Actions biochimiques/physiologiques

LY3000328 is an orally active, non-covalent, potent and selective cathepsin S (Cat S, Cat-S, CatS, CTSS) inhibitor (human/mouse CatS IC50 = 7.7/1.67 nM) that targets the S2 and S3 subsites without interacting with the active site Cys25. LY3000328 prevents high glucose-induced human aortic smooth muscle cells (SMCs) osteogenic transformation in cultures (1 µM) and displays in vivo therapeutic efficacy in murine models of CaCl2-induced abdominal aortic aneurysm (AAA) (1-10 mg/kg bid po) and CD4+ T cell-mediated colitis induction (0.1 mg/0.2 mL/mouse via daily i.p.).

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Christopher D Payne et al.
British journal of clinical pharmacology, 78(6), 1334-1342 (2014-07-22)
The aim of this study was to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of LY3000328 when administered as single escalating doses to healthy volunteers. This was a phase 1, placebo-controlled, dose escalation study with LY3000328 in 21 healthy
Santhosh Kumar Vr et al.
Journal of the American Society of Nephrology : JASN, 27(6), 1635-1649 (2015-11-15)
Endothelial dysfunction is a central pathomechanism in diabetes-associated complications. We hypothesized a pathogenic role in this dysfunction of cathepsin S (Cat-S), a cysteine protease that degrades elastic fibers and activates the protease-activated receptor-2 (PAR2) on endothelial cells. We found that
Xiaobing Yao et al.
Molecular medicine reports, 20(1), 141-150 (2019-05-23)
As a member of the cysteine protease family, cathepsin S (CTSS) serves an important role in diseases such as cancer, arthritis and atherosclerosis. Nevertheless, its role in renal fibrosis is unknown. In the present study, the effects of CTSS on
Prabhakar K Jadhav et al.
ACS medicinal chemistry letters, 5(10), 1138-1142 (2014-10-15)
Cathepsin S (Cat S) plays an important role in many pathological conditions, including abdominal aortic aneurysm (AAA). Inhibition of Cat S may provide a new treatment for AAA. To date, several classes of Cat S inhibitors have been reported, many

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique